NervGen Pharma’s lead drug candidate, NVG-291, is being evaluated in an ongoing Phase Ib/IIa clinical trial in partnership with Shirley Ryan AbilityLab for patients with spinal cord injury (SCI). Unlike traditional approaches that manage symptoms, NVG-291 empowers the nervous system to repair itself. DDW’s Megan Thomas speaks with President and CEO Mike Kelly about the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!